Navigation Links
PharmAthene Announces Proposed Common Stock Offering
Date:10/28/2010

ANNAPOLIS, Md., Oct. 28 /PRNewswire-FirstCall/ -- PharmAthene, Inc. (NYSE Amex: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. The offering is subject to market conditions and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Roth Capital Partners, LLC. is acting as sole underwriter for the offering.

The shares are being offered by PharmAthene pursuant to a shelf registration statement previously filed with and declared effective by the Securities and Exchange Commission ("SEC") on February 13, 2009. A preliminary prospectus supplement relating to the offering will be filed with the SEC and will be available on the SEC's website located at www.sec.gov. Copies of the preliminary prospectus supplement and the accompanying prospectus relating to this offering may be obtained from Roth Capital Partners, LLC Syndicate Department,  24 Corporate Plaza, Newport Beach, CA 92660, at 800-678-9147 and Rothecm@roth.com. Before you invest, you should read the prospectus and prospectus supplement in that registration statement and other documents PharmAthene has filed or will file with the SEC for more complete information about PharmAthene and the offering.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.

About PharmAthene, Inc.

PharmAthene was formed to meet
'/>"/>

SOURCE PharmAthene, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. PharmAthene Announces $3.9 Million Registered Direct Offering
2. PharmAthene CEO To Participate on Biosecurity Panel at the 2010 BIO International Conference
3. PharmAthene Appoints Mitchel Sayare, Ph.D. to the Companys Board of Directors
4. PharmAthene Reports Year-End 2009 Financial and Operational Results and Provides Update On Ongoing Litigation With SIGA Technologies
5. PharmAthene to Provide Update on SparVax(TM) Contract Modification Suspension During Year-End 2009 Financial and Operational Results Conference Call on Tuesday March 23, 2010
6. PharmAthene to Host Year-End 2009 Earnings Conference Call and Webcast on Tuesday, March 23, 2010
7. PharmAthene to Present at the 2010 Roth Capital Markets Growth Stock Conference on Monday, March 15, 2010
8. PharmAthene Submits White Paper to BARDA for Advanced Development Funding for SparVax(TM) - Novel Recombinant Protective Antigen Anthrax Vaccine
9. PharmAthene Appoints Jeffrey W. Runge, M.D. to the Companys Board of Directors
10. PharmAthene Announces Updated Time for Conference Call to Review BARDA rPA Decision
11. PharmAthene Reports Third Quarter 2009 Financial and Operational Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... 21, 2014 ... announced the addition of the  "Global Hormone ... offering.       (Logo: http://photos.prnewswire.com/prnh/20130307/600769) ,Hormone ... is a means of replacing hormones that ... body. This type of therapy is usually ...
(Date:8/21/2014)... , Aug. 21, 2014 Mathematic studies at ... Harvard University , and funded by the Jeffrey Epstein ... within tumors can be visually identified for elimination. These aggressive ... The study, which shows a topological map of what to ... in cancer research, for while tumor cells can be extracted ...
(Date:8/21/2014)... Ontotext S4 , The Self Service Semantic ... Now the same enterprise hardened text mining, Linked Data ... is available to start-ups and mid-size businesses at a ... do not have resources to evaluate and prototype enterprise ... there is no need for on premise hardware provisioning ...
(Date:8/20/2014)... of patented university inventions licensed to biotechnology firms ... commercialization. To open these roadblocks, the researchers suggest ... the discovery stage could lead to faster commercialization ... derived from discoveries made in university laboratories and ... during clinical trials, which have a high failure ...
Breaking Biology Technology:Global Hormone Replacement Therapy Market 2014-2018: Key Vendors are Actavis, Bayer, Merck & Co, Novartis and Novo Nordisk 2Science Power Jeffrey Epstein and Harvard University Fund Project to Visually Stop Tumor Growth 2Ontotext Releases Text Mining & Semantic Technology Running in the Cloud – Welcome to “S4? 2Ontotext Releases Text Mining & Semantic Technology Running in the Cloud – Welcome to “S4? 3Ontotext Releases Text Mining & Semantic Technology Running in the Cloud – Welcome to “S4? 4Early bottlenecks in developing biopharmaceutical products delay commercialization 2Early bottlenecks in developing biopharmaceutical products delay commercialization 3
... VEGAS, Aug. 11, 2011 Cord Blood America, Inc ... ), the umbilical cord blood stem cell preservation company ... cells to families nationwide and internationally, today announced revenues of ... 61 percent compared to revenues of $1.79 million in the ...
... involving scientists from The University of Nottingham is pioneering a ... reported in Nature Materials , could pave the way ... generation of computers and data storage devices that are faster, ... group, led by Dr Andrei Khlobystov in the University,s School ...
... Aug. 10, 2011 Genesis Biopharma, Inc. (OTC/BB: ... today announced it has signed a Cooperative Research ... Institute (NCI).  Under the terms of the five-year ... work with Steven A. Rosenberg, M.D., Ph.D., the ...
Cached Biology Technology:Cord Blood America Six Month Revenues Up 61 Percent; Gross Profit Up 100 Percent 2Cord Blood America Six Month Revenues Up 61 Percent; Gross Profit Up 100 Percent 3Nottingham scientists pioneer new method for nanoribbon production 2Genesis Biopharma Signs Cooperative Research and Development Agreement With the National Cancer Institute to Develop Cancer Immunotherapies 2Genesis Biopharma Signs Cooperative Research and Development Agreement With the National Cancer Institute to Develop Cancer Immunotherapies 3
(Date:8/20/2014)... OTTAWA , Aug. 20, 2014 /CNW/ -  ... without warning and can quickly become life threatening for some ... As many as 1.2 million Canadians have food allergies and ... six per cent of children are estimated to have food ... range from mild skin irritations and hives to breathing difficulties ...
(Date:8/20/2014)... VALLEY, Calif., August 19, 2014 -- Bay Area Lyme ... diagnose and simple to cure, applauds new research published ... journal Ticks and Tick-borne Diseases . The ... Northwest California are active throughout the year, making the ... by researchers at California Department of Public Health (CDPH) ...
(Date:8/20/2014)... and seawater signals a relaxing trip to the shore. ... vacation comes with an environmental hitch. When certain sunblock ... can become toxic to some of the ocean,s tiniest ... marine animals. Their study appears in the ACS journal ... and David Snchez-Quiles point out that other than staying ...
Breaking Biology News(10 mins):Information Update - Allergens and food safety at school - What's in your child's lunch? 2Information Update - Allergens and food safety at school - What's in your child's lunch? 3Lyme disease risk is year-round in Northwest California, according to new study 2Lyme disease risk is year-round in Northwest California, according to new study 3
... 2008A landmark genetic study has identified multiple genes linked ... autoimmune disease that affects an estimated 1.4 million Americans. ... lungs, brain and blood and occurs in about 31 ... more likely than men to develop the condition, which ...
... available in French . , A study ... differences between individuals at the DNA level can lead ... These, in turn, are responsible for the vast array ... part of the Genome Regulators in Disease (GRID) Project ...
... from the January issue of Mayo Clinic Proceedings include ... workplace drug screening and the safety and effectiveness of ... Examine the Effect of Antioxidant Supplements on Cancer ... cancer and deaths related to cancer? Thats a question ...
Cached Biology News:Steps toward Stopping Autoimmune Disease 2Tiny genetic differences have huge consequences: McGill researchers 2Mayo Clinic Proceedings January tip sheet 2Mayo Clinic Proceedings January tip sheet 3
Anti-Mouse C-10, Biotin (Polyclonal) (rabbit IgG)...
... ADAMTS16 ( Abpromise for all ... Synthetic peptide based on the ... the amino acid sequence is proprietary) ... 170690 SWISS Protein ...
Purified Mouse anti-Hu Actopaxin (pS8) Storage Temperature: Refrigerate(2 to 8C)...
Hamartin/TSC1 (1B2) Mouse mAb Ship: Hot Store: -20 C...
Biology Products: